Jasper Therapeutics Stock Scheduled to Reverse Split on Friday, November 6th (NASDAQ:JSPR)

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) are scheduled to reverse split on Friday, November 6th. The 1-30 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 5th.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR traded up $0.03 during mid-day trading on Wednesday, reaching $0.51. 767,002 shares of the company’s stock were exchanged, compared to its average volume of 795,539. The firm has a market capitalization of $17.01 million, a price-to-earnings ratio of -0.32 and a beta of 3.30. Jasper Therapeutics has a 52 week low of $0.32 and a 52 week high of $2.42. The firm has a 50-day moving average price of $0.59 and a two-hundred day moving average price of $0.85.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, sell-side analysts forecast that Jasper Therapeutics will post -0.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JSPR. Piper Sandler began coverage on shares of Jasper Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 target price for the company. William Blair started coverage on Jasper Therapeutics in a research note on Wednesday, October 14th. They issued an “outperform” rating on the stock. Wall Street Zen upgraded Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Jasper Therapeutics currently has an average rating of “Hold” and an average price target of $7.33.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.